Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited. Major factors driving the market growth include the increasing prevalence of cancer and increasing preference for chemotherapy. Additionally, the growing clinical trials for chemotherapeutic drugs is likely to emerge as a significant future trend in the market during the forecast period. However, lack of consolidated guidelines for chemotherapy hamper the chemotherapy induced peripheral neuropathy market growth.
WEX Pharmaceuticals, Inc. and Regency Pharmaceutical, Inc. – Notable Market Players in Chemotherapy Induced Peripheral Neuropathy Market
The chemotherapy induced peripheral neuropathy market is majorly comprised of top players involving Regenacy Pharmaceuticals, Inc, Asahi Kasei Pharma Corporation., Novaremed, Makscientific, Llc, Wex Pharmaceuticals Inc., Sova Pharmaceuticals, Inc., Kineta, Inc., Aptinyx Inc., Apexian Pharmaceuticals, Inc., and Winsantor, Inc. among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the chemotherapy induced peripheral neuropathy market:
| Year | News |
| Jan-2021 | Novaremed AG, a clinical-stage Swiss biopharmaceutical company, signed a $50 million capital commitment agreement with GEM Global Yield LLC SCS (GEM), a Luxembourg-based private alternative investment group, in January 2021. Novaremed receives a $50 million investment from Global Emerging Markets |
| April-2021 | WEX Pharmaceuticals Inc. announced that two clinical trials on tetrodotoxin (TTX) as a therapeutic agent had been published in a special issue of the Toxins Journal. The cardiac safety study “Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults” was included in the special edition of the Toxins Journal, as was the study “Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding WEX.” |
| Jul-2021 | Kineta Inc announced that the first participant in a Phase 1 multiple ascending dose (MAD) clinical trial of KCP506, an investigational, first-in-class nicotinic acetylcholine receptor (nAChR) antagonist in development for the treatment of chronic neuropathic pain, had been dosed successfully. The first participant in Kineta’s Phase 1 Multiple Ascending Dose Clinical Trial of KCP506 has been dosed |
| Mar-2022 | Asahi Kasei Pharma Open new window announced that study drug administration has begun for the first patient in the Japan-US international phase 1 study of ART-123 (generic name: thrombomodulin alfa; marketed as Recomodulin Injection in Japan)1) for the prevention of sensory symptoms of chemotherapy-induced peripheral neuropathy (CIPN) being performed jointly with Veloxis Pharmaceuticals, Inc., wholly-owned subsidiary of Asahi Kasei Corp. (SENSEible mCRC Study,2) in the future “the Study”) |
